The Efficacy and Controversy of Octreotide and Somatostatin Analogues in the Treatment of Chronic Pancreatitis: A Review

Read full text Summarise with VIRAT
Authors: S. Kusuma kumari Kasula Satwika*
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic pancreatitis (CP) is a progressive fibro-inflammatory disease of the pancreas that causes chronic pain, maldigestion, endocrine insufficiency and frequent local complications such as pseudocysts and fistulae. Octreotide (a synthetic somatostatin analogue) and somatostatin reduce pancreatic exocrine secretion through somatostatin receptor–mediated mechanisms, and have been evaluated for symptom control, complication prevention and perioperative use in pancreatic surgery. Available data show biologically plausible effects (reduced pancreatic enzyme output and modulation of inflammation), clearer benefit in some acute and perioperative contexts (reduced postoperative pancreatic fistula in several trials), but heterogeneous and inconsistent results in chronic pancreatitis for long-term pain control and complication prevention

Fields of Study & Subjects

Pancreatitis Pathology and Treatment Pancreatic and Hepatic Oncology Research IgG4-Related and Inflammatory Diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN